Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul W Estes

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Alzheimer'S Research & Therapy|May 20, 2026
Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivityPaul W Estes
World Journal of Psychiatry|January 21, 2020
Validity, reliability, and psychometric properties of a computerized, cognitive assessment test (Cognivue<sup>®</sup>)Diego Cahn-Hidalgo, Paul W Estes, Reina Benabou
Neurology and Therapy|April 7, 2025
The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue ClarityJames E Galvin, Michael J Kleiman, Heather M Harris, et al.
Journal of Alzheimer'S Disease : JAD|January 27, 2025
Cognivue <i>Clarity</i><sup>®</sup> characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes StudyJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Scientific Reports|October 18, 2024
Cognivue Clarity characterizes mild cognitive impairment and Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes StudyJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Alzheimer'S Research & Therapy|May 20, 2026
Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivityPaul W Estes
World Journal of Psychiatry|January 21, 2020
Validity, reliability, and psychometric properties of a computerized, cognitive assessment test (Cognivue<sup>®</sup>)Diego Cahn-Hidalgo, Paul W Estes, Reina Benabou
Neurology and Therapy|April 7, 2025
The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue ClarityJames E Galvin, Michael J Kleiman, Heather M Harris, et al.
Journal of Alzheimer'S Disease : JAD|January 27, 2025
Cognivue <i>Clarity</i><sup>®</sup> characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes StudyJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Scientific Reports|October 18, 2024
Cognivue Clarity characterizes mild cognitive impairment and Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes StudyJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersJames E Galvin, Michael J Kleiman, Paul W Estes, et al.
Pageof 1